{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:09:28Z","timestamp":1788786568729,"version":"build-2803163510"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Pulmonary fungal diseases remain associated with substantial morbidity and mortality, particularly in immunocompromised individuals, transplant recipients, and critically ill patients. Although systemic antifungal therapy remains the cornerstone of treatment, its effectiveness may be limited by suboptimal penetration into selected pulmonary compartments, while systemic toxicity, drug\u2013drug interactions, and prolonged treatment requirements may restrict therapeutic options. Aerosolized antifungal therapy provides a pharmacologically attractive approach to increase local pulmonary drug exposure while limiting systemic exposure. Among currently available formulations, liposomal amphotericin B has the most extensive clinical experience for inhaled administration, supported by favorable pulmonary retention, respiratory tolerability, and compatibility with contemporary nebulization technologies. Advances in vibrating mesh nebulizers and aerosol delivery during invasive mechanical ventilation and high-flow respiratory support have further improved the technical feasibility of targeted pulmonary drug administration. Current clinical evidence is strongest for prophylaxis of invasive pulmonary aspergillosis in selected high-risk populations, particularly patients with prolonged neutropenia. Aerosolized amphotericin B formulations are also incorporated into prophylactic strategies after lung transplantation, although protocols remain heterogeneous and evidence is predominantly observational. By contrast, therapeutic applications beyond prophylaxis remain investigational. The potential role of aerosolized therapy differs substantially among pulmonary fungal diseases according to pathogen biology, anatomical distribution, host characteristics, and accessibility of the affected pulmonary compartment. Chronic pulmonary aspergillosis may provide a rationale for localized drug delivery, but cavitary disease and heterogeneous ventilation may limit aerosol deposition. For pulmonary mucormycosis, cryptococcosis,\n                    <jats:italic>Pneumocystis jirovecii<\/jats:italic>\n                    pneumonia, and endemic mycoses, current evidence is insufficient to support routine inhaled antifungal therapy. This Mini Review summarizes current evidence on aerosolized antifungal formulations, pulmonary pharmacology, nebulization technologies, and disease-specific clinical applications, while highlighting current limitations and priorities for future translational and clinical research.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2026.1937682","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:14:15Z","timestamp":1788412455000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Aerosolized antifungal therapy in pulmonary fungal disease: pharmacology, drug delivery and emerging clinical applications"],"prefix":"10.3389","volume":"13","author":[{"given":"Massimo","family":"Caracciolo","sequence":"first","affiliation":[{"name":"Anesthesia and Post-Operative Care Unit, Villa Sant'Anna Hospital","place":["Reggio Calabria, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Antonella","family":"Caracciolo","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Intensive Care, Santa Maria Nuova Hospital","place":["Reggio Emilia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Francesca","family":"Stagno","sequence":"additional","affiliation":[{"name":"UOSD Post-Operative Intensive Care Unit, Great Metropolitan Hospital \u201cBianchi Melacrino Morelli\u201d","place":["Reggio Calabria, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Pellicano","sequence":"additional","affiliation":[{"name":"UOSD Post-Operative Intensive Care Unit, Great Metropolitan Hospital \u201cBianchi Melacrino Morelli\u201d","place":["Reggio Calabria, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Ripepi","sequence":"additional","affiliation":[{"name":"UOSD Post-Operative Intensive Care Unit, Great Metropolitan Hospital \u201cBianchi Melacrino Morelli\u201d","place":["Reggio Calabria, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Pellicano","sequence":"additional","affiliation":[{"name":"UOSD Post-Operative Intensive Care Unit, Great Metropolitan Hospital \u201cBianchi Melacrino Morelli\u201d","place":["Reggio Calabria, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Scopelliti","sequence":"additional","affiliation":[{"name":"UOSD Post-Operative Intensive Care Unit, Great Metropolitan Hospital \u201cBianchi Melacrino Morelli\u201d","place":["Reggio Calabria, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Elvira","family":"Serran\u00f2","sequence":"additional","affiliation":[{"name":"UOSD Post-Operative Intensive Care Unit, Great Metropolitan Hospital \u201cBianchi Melacrino Morelli\u201d","place":["Reggio Calabria, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Loddo","sequence":"additional","affiliation":[{"name":"UOSD Post-Operative Intensive Care Unit, Great Metropolitan Hospital \u201cBianchi Melacrino Morelli\u201d","place":["Reggio Calabria, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano La","family":"Scala","sequence":"additional","affiliation":[{"name":"UOSD Post-Operative Intensive Care Unit, Great Metropolitan Hospital \u201cBianchi Melacrino Morelli\u201d","place":["Reggio Calabria, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1086\/586739","article-title":"Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial","volume":"46","author":"Rijnders","year":"2008","journal-title":"Clin Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s12281-019-00354-6","article-title":"Inhaled antifungal therapy: an update","volume":"13","author":"Clark","year":"2019","journal-title":"Curr Fungal Infect Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"102233","DOI":"10.1016\/j.pupt.2023.102233","article-title":"Safety and usefulness of nebulized liposomal amphotericin B: systematic scoping review","volume":"82","author":"Hagiya","year":"2023","journal-title":"Pulm Pharmacol Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3390\/jof9040464","article-title":"Clinical uses of inhaled antifungals for invasive pulmonary fungal disease: promises and challenges","volume":"9","author":"Vuong","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1697842","DOI":"10.3389\/fmed.2025.1697842","article-title":"Successful ventilator weaning after aerosolized liposomal amphotericin B in persistent Candida glabrata colonization: a case report","volume":"12","author":"Caracciolo","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1796594","DOI":"10.3389\/fmed.2026.1796594","article-title":"Multidistrict invasive Candida glabrata infection successfully treated with echinocandin and liposomal amphotericin B combination therapy: a case report and therapeutic perspective","volume":"13","author":"Caracciolo","year":"2026","journal-title":"Front Med (Lausanne)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1016\/S1473-3099(24)00749-7","article-title":"Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM","volume":"25","author":"Cornely","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1164\/ajrccm.156.2.9612023","article-title":"Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study","volume":"156","author":"El-Ebiary","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40262-017-0578-5","article-title":"Clinical pharmacokinetics and pharmacodynamics of echinocandins","volume":"57","author":"Wasmann","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1128\/CMR.00046-13","article-title":"Tissue penetration of antifungal agents","volume":"27","author":"Felton","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.1128\/AAC.01087-07","article-title":"Penetration of amphotericin B lipid formulations into pleural effusion","volume":"51","author":"Weiler","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"B14","doi-asserted-by":"publisher","first-page":"ofaa656","DOI":"10.1093\/ofid\/ofaa656","article-title":"Candida empyema thoracis at two academic medical centers: new insights into treatment and outcomes","volume":"8","author":"Senger","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"127038","DOI":"10.1016\/j.micres.2022.127038","article-title":"Candida glabrata is a successful pathogen: an artist manipulating the immune response","volume":"260","author":"Castrej\u00f3n-Jim\u00e9nez","year":"2022","journal-title":"Microbiol Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.4049\/jimmunol.1003730","article-title":"The facultative intracellular pathogen Candida glabrata subverts macrophage cytokine production and phagolysosome maturation","volume":"187","author":"Seider","year":"2011","journal-title":"J Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"fov042","DOI":"10.1093\/femsyr\/fov042","article-title":"Intracellular survival of Candida glabrata in macrophages: immune evasion and persistence","volume":"15","author":"Kasper","year":"2015","journal-title":"FEMS Yeast Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1128\/IAI.01244-09","article-title":"Candida glabrata persistence in mice does not depend on host immunosuppression and is unaffected by fungal amino acid auxotrophy","volume":"78","author":"Jacobsen","year":"2010","journal-title":"Infect Immun"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e00277","DOI":"10.1128\/mSphere.00277-19","article-title":"Atomic force microscopy demonstrates that Candida glabrata uses three epa proteins to mediate adhesion to abiotic surfaces","volume":"4","author":"Valotteau","year":"2019","journal-title":"mSphere"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e1000268","DOI":"10.1371\/journal.ppat.1000268","article-title":"Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence","volume":"5","author":"Ferrari","year":"2009","journal-title":"PLoS Pathog"},{"key":"B21","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/j.1567-1364.2006.00117.x","article-title":"Candida biofilms on implanted biomaterials: a clinically significant problem","volume":"6","author":"Ramage","year":"2006","journal-title":"FEMS Yeast Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/jof6010021","article-title":"Contributions of the biofilm matrix to Candida pathogenesis","volume":"6","author":"Nett","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3201\/eid0809.020063","article-title":"Biofilms: microbial life on surfaces","volume":"8","author":"Donlan","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/17476348.2023.2183194","article-title":"Not all nebulizers are created equal: considerations in choosing a nebulizer for aerosol delivery during mechanical ventilation","volume":"17","author":"MacLoughlin","year":"2023","journal-title":"Expert Rev Respir Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"588","DOI":"10.21037\/atm-20-5665","article-title":"Aerosol delivery via invasive ventilation: a narrative review","volume":"9","author":"Lin","year":"2021","journal-title":"Ann Transl Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1186\/s13054-020-03206-9","article-title":"A narrative review on trans-nasal pulmonary aerosol delivery","volume":"24","author":"Li","year":"2020","journal-title":"Crit Care"},{"key":"B27","doi-asserted-by":"publisher","first-page":"590","DOI":"10.21037\/atm-20-7383","article-title":"Narrative review of practical aspects of aerosol delivery via high-flow nasal cannula","volume":"9","author":"Li","year":"2021","journal-title":"Ann Transl Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1089\/jamp.2017.1366","article-title":"Aerosol delivery with two nebulizers through high-flow nasal cannula: a randomized cross-over single-photon emission computed tomography-computed tomography study","volume":"30","author":"Dugernier","year":"2017","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4187\/respcare.09133","article-title":"The impact of high-flow nasal cannula device, nebulizer type, and placement on trans-nasal aerosol drug delivery","volume":"67","author":"Li","year":"2022","journal-title":"Respir Care"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1098427","DOI":"10.3389\/fmed.2022.1098427","article-title":"Aerosol delivery through high-flow nasal therapy: technical issues and clinical benefits","volume":"9","author":"Calabrese","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"9482","DOI":"10.1038\/s41598-019-45890-w","article-title":"Antifungal synergy of a topical triazole, PC945, with a systemic triazole against respiratory Aspergillus fumigatus infection","volume":"9","author":"Colley","year":"2019","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/jof6040373","article-title":"PC945, A novel inhaled antifungal agent, for the treatment of respiratory fungal infections","volume":"6","author":"Murray","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1136\/thorax-2021-218375","article-title":"Novel inhaled antifungal for pseudomembranous Aspergillus tracheobronchitis complicating connective tissue disease","volume":"78","author":"Singh","year":"2023","journal-title":"Thorax"},{"key":"B34","doi-asserted-by":"publisher","first-page":"858","DOI":"10.4187\/respcare.03790","article-title":"Aerosol therapy in pulmonary critical care","volume":"60","author":"Ari","year":"2015","journal-title":"Respir Care"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1007\/s00134-013-2872-5","article-title":"Aerosol therapy during mechanical ventilation: an international survey","volume":"39","author":"Ehrmann","year":"2013","journal-title":"Intensive Care Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/CPM.0000000000000085","article-title":"Aerosol drug delivery during mechanical ventilation: devices, selection, delivery technique and evaluation of clinical response to therapy","volume":"22","author":"Ari","year":"2015","journal-title":"Clin Pulm Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13613-023-01147-4","article-title":"Aerosol therapy in adult critically ill patients: a consensus statement regarding aerosol administration strategies during various modes of respiratory support","volume":"13","author":"Li","year":"2023","journal-title":"Ann Intensive Care"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"Denning","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/thoraxjnl-2014-206291","article-title":"The clinical spectrum of pulmonary aspergillosis","volume":"70","author":"Kosmidis","year":"2015","journal-title":"Thorax"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2003345","DOI":"10.1183\/13993003.03345-2020","article-title":"Chronic pulmonary aspergillosis: prevalence, favouring pulmonary diseases and prognosis","volume":"58","author":"Maitre","year":"2021","journal-title":"Eur Respir J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"124938","DOI":"10.1016\/j.ijpharm.2024.124938","article-title":"Posaconazole nanocrystals dry powder inhalers for the local treatment of invasive pulmonary aspergillosis","volume":"668","author":"Li","year":"2025","journal-title":"Int J Pharm"},{"key":"B42","author":"Husain","year":"2026"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2600058","DOI":"10.1183\/13993003.00058-2026","article-title":"Safety and efficacy of inhaled itraconazole in adults with asthma and allergic bronchopulmonary aspergillosis (PUR1900-ABPA): a randomized, double-blind, parallel-group, placebo-controlled, multicenter, phase 2 trial","author":"Agarwal","year":"2026","journal-title":"Eur Respir J"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1937682\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:31:04Z","timestamp":1788784264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1937682\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":43,"alternative-id":["10.3389\/fmed.2026.1937682"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1937682","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1937682"}}